Outlook Therapeutics (OTLK) Depreciation & Amortization (CF) (2015 - 2026)
Outlook Therapeutics (OTLK) reported Depreciation & Amortization (CF) of $30417.0 for Q1 2026, up 4.52% year-over-year from $29102.0 in Q1 2025, and up 1.14% quarter-over-quarter from $30074.0 in Q4 2025.
Outlook Therapeutics (OTLK) Depreciation & Amortization (CF) (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 12 years of Depreciation & Amortization (CF) data on file, last reported at $30417.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $30417.0, up 4.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $119640.0 (up 3.7% YoY), and the FY2025 annual result was $117052.0, up 2.8% from the prior year.
- Depreciation & Amortization (CF) climbed to $30417.0 in Q1 2026 per OTLK's latest filing, from $30074.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $51470.0 in Q3 2022 and troughed at $10778.0 in Q4 2022.
- A 5-year average of $28789.2 and a median of $28801.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) sank 78.81% in 2022, then jumped 161.6% in 2023.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $10778.0 in 2022, then soared by 161.6% to $28195.0 in 2023, then grew by 2.15% to $28801.0 in 2024, then grew by 4.42% to $30074.0 in 2025, then gained by 1.14% to $30417.0 in 2026.
- Business Quant data shows OTLK's Depreciation & Amortization (CF) at $30417.0 in Q1 2026, $30074.0 in Q4 2025, and $29737.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 1,395.22 |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 429,663.65 |
| 10 | Outlook Therapeutics | 51.13 Mn | 43.39 Mn | -21,888.00 | 30,417.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30,417.00 |
| Mar 31, 2026 | 30,417.00 |
| Dec 31, 2025 | 30,074.00 |
| Dec 31, 2025 | 30,074.00 |
| Sep 30, 2025 | 29,737.00 |
| Sep 30, 2025 | 29,737.00 |
| Jun 30, 2025 | 29,412.00 |
| Jun 30, 2025 | 29,412.00 |
| Mar 31, 2025 | 29,102.00 |
| Mar 31, 2025 | 29,102.00 |
| Dec 31, 2024 | 28,801.00 |
| Dec 31, 2024 | 28,801.00 |
| Sep 30, 2024 | 28,797.00 |
| Sep 30, 2024 | 28,797.00 |
| Jun 30, 2024 | 28,672.00 |
| Jun 30, 2024 | 28,672.00 |
| Mar 31, 2024 | 28,195.00 |
| Mar 31, 2024 | 28,195.00 |
| Dec 31, 2023 | 28,195.00 |
| Dec 31, 2023 | 28,195.00 |